// App-Quantinova.ai

P6-12-02 : Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC)

Researchers

Presenter

  • Isakoff SJ

Principal Investigators

  • Bendell JC

  • Cervantes ASoria J-CMolife LR

  • Sanabria-Bohorquez SM

  • Punnoose EA

  • Jia S

  • Patel P

  • Saura C

Medical Centers

  • Hospital Clinico Universitario, Valencia, Valencia, Spain

  • Vall dHebron University Hospital, Barcelona, SpainSarah Cannon Research Institute, Nashville, TNMassachusetts General Hospital Cancer Center, Boston, MA

  • Institut Gustave-Roussy, Villejuif, France

  • Genentech, San Francisco, CA

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United States

  • Spain

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Triple-negative breast cancer

Biomarkers

  • Phosphatase and tensin homolog

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Ipatasertib

  • Paclitaxel

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Genentech

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved